SEC Info  
   Home     Search     My Interests     Help     Sign In     Please Sign In  

Applied Biosystems Inc. · S-4/A · On 3/19/99

Filed On 3/19/99   ·   Accession Number 1047469-99-10576   ·   SEC File 333-67797

  in   Show  and 
Help... Wildcards:  ? (any letter),  * (many).  Logic:  for Docs:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).
 
  As Of                Filer                Filing    For/On/As Docs:Size              Issuer               Agent

 3/19/99  Applied Biosystems Inc.           S-4/A                  2:79K                                    Merrill Corp/New/FA

Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction   —   Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration of             4     21K 
                          Securities Issued in a                                 
                          Business-Combination Transaction                       
 2: EX-10.5     Material Contract                                     29     85K 


S-4/A   —   Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction

S-4/A1st Page of 4TOCTopPreviousNextBottomJust 1st
 

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 19, 1999 REGISTRATION NO. 333-67797 -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ PE CORPORATION (FORMERLY KNOWN AS THE PERKIN-ELMER CORPORATION) (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) [Download Table] DELAWARE 3826 06--1534213 (STATE OR OTHER JURISDICTION (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER OF CLASSIFICATION CODE NUMBER) IDENTIFICATION INCORPORATION OR ORGANIZATION) NO.) ------------------------ PE CORPORATION 761 MAIN AVENUE NORWALK, CT 06859-0001 (203) 762-1000 ---------------------------------- (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) WILLIAM B. SAWCH 761 MAIN AVENUE NORWALK, CT 06859-0001 (203) 761-2900 (NAME AND ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE) ------------------------------ WITH COPIES TO: RAYMOND W. WAGNER FRANCIS J. MORISON SIMPSON THACHER & BARTLETT DAVIS POLK & WARDWELL 425 LEXINGTON AVENUE 450 LEXINGTON AVENUE NEW YORK, NEW YORK 10017 NEW YORK, NEW YORK 10017 ---------------------------------- APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: AS SOON AS PRACTICABLE AFTER THE REGISTRATION STATEMENT BECOMES EFFECTIVE. ---------------------------------- If any of the securities being registered on this form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box: / / ---------------------------------- If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: / / ---------------------------------- If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: / / ---------------------------------- CALCULATION OF REGISTRATION FEE [Enlarge/Download Table] PROPOSED MAXIMUM PROPOSED MAXIMUM TITLE OF EACH CLASS OF AMOUNT TO OFFERING PRICE AGGREGATE SECURITIES TO BE REGISTERED BE REGISTERED PER SHARE OFFERING PRICE PE Corporation-PE Biosystems Group Common Stock, par value $.01 per share (1).............................. N/A N/A N/A Rights to Purchase Series A Participating Junior Preferred Stock, par value $.01 per share (2)......... N/A N/A N/A PE Corporation-Celera Genomics Group Common Stock, par value $.01 per share (1)(3)........................... N/A N/A $333,667,000 Rights to Purchase Series B Participating Junior Preferred Stock, par value $.01 per share (2)......... N/A N/A N/A TITLE OF EACH CLASS OF AMOUNT OF SECURITIES TO BE REGISTERED REGISTRATION FEE PE Corporation-PE Biosystems Group Common Stock, par value $.01 per share (1).............................. N/A Rights to Purchase Series A Participating Junior Preferred Stock, par value $.01 per share (2)......... N/A PE Corporation-Celera Genomics Group Common Stock, par value $.01 per share (1)(3)........................... $92,800 Rights to Purchase Series B Participating Junior Preferred Stock, par value $.01 per share (2)......... N/A (1) If the Recapitalization Proposal described herein is approved by the shareholders and the reincorporation merger (the "Merger") of The Perkin-Elmer Corporation, a New York corporation ("Perkin-Elmer New York"), with a subsidiary of PE Corporation, a Delaware corporation ("PE Delaware"), becomes effective, each share of the Common Stock, par value $1.00 per share, of Perkin-Elmer New York (the "Existing Common Stock"), outstanding at the effective time (the "Effective Time") of the Merger will be converted into one share of PE Corporation-PE Biosystems Group Common Stock, par value $.01 per share ("PE Biosystems Stock"), and .5 of a share (the "Ratio") of PE Corporation-Celera Genomics Group Common Stock, par value $.01 per share ("Celera Genomics Stock"). The number of shares of PE Biosystems Stock being registered is equal to the number of shares of Existing Common Stock outstanding at the Effective Time, and the number of shares of Celera Genomics Stock being registered is equal to the Ratio times the number of shares of Existing Common Stock outstanding at the Effective Time. In accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"), the number of shares being registered is not included in the table. (2) Prior to the occurrence of certain events, the rights to purchase Series A Participating Junior Preferred Stock, par value $.01 per share, and the rights to purchase Series B Participating Junior Preferred Stock, par value $.01 per share (collectively, the "Rights"), will not be evidenced separately from the related PE Biosystems Stock or Celera Genomics Stock. The value, if any, of the Rights is reflected in the market price of the related PE Biosystems Stock or Celera Genomics Stock. Accordingly, no separate fee is paid. (3) Previously paid based upon the book value of Perkin-Elmer New York's historical interests in the Celera Genomics Group of $333,667,000 as of September 30, 1998. THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE. -------------------------------------------------------------------------------- --------------------------------------------------------------------------------
S-4/A2nd Page of 4TOC1stPreviousNextBottomJust 2nd
This Amendment No. 3 is being filed solely for the purpose of filing Exhibit No. 10.5
S-4/A3rd Page of 4TOC1stPreviousNextBottomJust 3rd
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 3 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Norwalk, State of Connecticut, on March 19, 1999. PE CORPORATION (formerly known as The Perkin-Elmer Corporation) By /s/ WILLIAM B. SAWCH as Attorney-In-Fact ----------------------------------------- Name: Tony L. White Title: Chairman of the Board, President and Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 3 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated. SIGNATURE TITLE DATE ------------------------------ --------------------------- ------------------- /s/ WILLIAM B. SAWCH as Attorney-In-Fact ------------------------------ Chairman of the Board of March 19, 1999 Tony L. White Directors, President and Chief Executive Officer (principal executive officer) /s/ DENNIS L. WINGER ------------------------------ Senior Vice President and March 19, 1999 Dennis L. Winger Chief Financial Officer (principal financial officer) /s/ UGO D. DEBLASI ------------------------------ Corporate Controller March 19, 1999 Ugo D. DeBlasi (principal accounting officer) /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Joseph F. Abely, Jr. /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Richard H. Ayers /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Jean-Luc Belingard /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Robert H. Hayes /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Georges C. St. Laurent, Jr. II-4
S-4/ALast Page of 4TOC1stPreviousNextBottomJust 4th
SIGNATURE TITLE DATE ------------------------------ --------------------------- ------------------- /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Carolyn W. Slayman /s/ WILLIAM B. SAWCH as Attorney-In-Fact Director ------------------------------ March 19, 1999 Orin R. Smith II-5

Dates Referenced Herein   and   Documents Incorporated By Reference

Referenced-On Page
This S-4/A Filing   Date First   Last      Other Filings
9/30/98110-Q
Filed On / Filed As Of3/19/9914
 
TopList All Filings


Filing Submission 0001047469-99-010576   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2014 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat, 1 Nov 02:11:59.0 GMT